We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+42.89%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$4.69B
AUM Growth
+$937M
Cap. Flow
+$184M
Cap. Flow %
3.93%
Top 10 Hldgs %
46.5%
Holding
101
New
13
Increased
10
Reduced
7
Closed
20

Top Buys

Rank Stock Value
1
LEGN icon
Legend Biotech
LEGN
+$110M
2
THRD
Third Harmonic Bio
THRD
+$62.6M
3
COGT icon
Cogent Biosciences
COGT
+$55M
4
FULC icon
Fulcrum Therapeutics
FULC
+$50.1M
5
BIIB icon
Biogen
BIIB
+$44.7M

Top Sells

Rank Stock Value
1
VERU icon
Veru
VERU
+$89.3M
2
PNT
POINT Biopharma Global Inc. Common Stock
PNT
+$61.3M
3
NTRA icon
Natera
NTRA
+$46.4M
4
DYN icon
Dyne Therapeutics
DYN
+$19.3M
5
GH icon
Guardant Health
GH
+$19.2M

Sector Composition

Rank Sector Weight
1 Healthcare 98.68%
2 Financials 0.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
26
DELISTED
Verona Pharma
VRNA
$61.8M 1.32%
6,050,000
+950,000
+19% +$8.01M
COGT icon
27
Cogent Biosciences
COGT
$6.65B
$59.9M 1.28%
+4,013,453
New +$55M
NSTG
28
DELISTED
NanoString Technologies, Inc.
NSTG
$58.8M 1.25%
4,602,478
+1,018,000
+28% +$14.1M
CLDX icon
29
Celldex Therapeutics
CLDX
$2.99B
$58.3M 1.24%
2,075,000
– –
GHRS icon
30
GH Research
GHRS
$1.93B
$56.9M 1.21%
4,898,373
– –
FULC icon
31
Fulcrum Therapeutics
FULC
$273M
$56.6M 1.21%
+7,000,000
New +$50.1M
KNTE
32
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$51M 1.09%
4,264,144
– –
ENTA icon
33
Enanta Pharmaceuticals
ENTA
$366M
$46.5M 0.99%
896,724
– –
DSGN icon
34
Design Therapeutics
DSGN
$761M
$46.4M 0.99%
2,773,231
+586,595
+27% +$11.7M
ETNB
35
DELISTED
89bio
ETNB
$45.1M 0.96%
7,782,669
– –
VOR icon
36
Vor Biopharma
VOR
$1.15B
$44.3M 0.94%
556,049
– –
CLYM
37
Climb Bio
CLYM
$681M
$42.5M 0.91%
13,150,849
– –
TIL icon
38
Instil Bio
TIL
$48.3M
$37.1M 0.79%
383,540
– –
RXST icon
39
RxSight
RXST
$249M
$36.6M 0.78%
3,052,796
– –
STSA
40
DELISTED
Satsuma Pharmaceuticals, Inc. Common Stock
STSA
$35.5M 0.76%
5,914,252
– –
RNAM
41
DELISTED
Avidity Biosciences
RNAM
$35.4M 0.76%
2,167,391
– –
VERA icon
42
Vera Therapeutics
VERA
$2.3B
$33.6M 0.72%
1,578,820
– –
RCKT icon
43
Rocket Pharmaceuticals
RCKT
$340M
$33.6M 0.72%
2,107,149
– –
AKRO
44
DELISTED
Akero Therapeutics
AKRO
$32.7M 0.7%
+958,980
New +$14.7M
ALPN
45
DELISTED
Alpine Immune Sciences Inc
ALPN
$31.4M 0.67%
+4,356,632
New +$35.9M
HLVX
46
DELISTED
HilleVax
HLVX
$30.1M 0.64%
1,760,019
– –
ACET icon
47
Adicet Bio
ACET
$85.2M
$29.3M 0.62%
+128,711
New +$32.7M
EYPT icon
48
EyePoint Inc
EYPT
$1.03B
$26.7M 0.57%
3,370,506
– –
MIST icon
49
Milestone Pharmaceuticals
MIST
$138M
$20.6M 0.44%
2,246,503
– –
PMVP icon
50
PMV Pharmaceuticals
PMVP
$59.2M
$20.4M 0.43%
1,710,265
– –
1
2
3 4 5

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2022 Portfolio in Review

As of Q3 2022, RA Capital Management held 101 positions worth $4.69B, up 25% from $3.75B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

RA Capital Management deployed $184M of net new capital in Q3 2022, opening 13 new positions and adding to 10 existing holdings. Its largest new stake was Legend Biotech: 2,338,610 shares worth $95.4M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Financials.

On the sell side, the largest reduction was Concert Pharmaceuticals, Inc., an estimated $13.5M trimmed.

  • RA Capital Management's largest Q3 2022 buy was Legend Biotech: 2,338,610 shares worth $95.4M.
  • RA Capital Management added most to Biogen in Q3 2022, an estimated $44.7M increase.
  • RA Capital Management's biggest Q3 2022 reduction was Concert Pharmaceuticals, Inc., cutting an estimated $13.5M.
  • RA Capital Management fully exited Veru in Q3 2022, selling an estimated $89.3M.
  • RA Capital Management's ten largest holdings make up 46% of its $4.69B portfolio in Q3 2022.
  • RA Capital Management opened 13 new positions and closed 20 in Q3 2022.
  • RA Capital Management's portfolio value rose 25% quarter-over-quarter to $4.69B.

Based on RA Capital Management's 13F filing for Q3 2022, filed 14 Nov 2022.